Case Report: Secukinumab (Interleukin-17 Inhibitor) and Ulcerative Colitis Flare – the Double-Edged Sword
This case highlights the emerging evidence of IL-17A blockade in IBD, potentially leading to adverse events, and adds to the growing body of evidence regarding the management of such complications with novel therapeutic approaches in severe cases. Physicians should be aware of this possibility when using IL-17A blockade in patients with pre-existing IBD.
Authors
- Péter L. Lakatos (ORCID: https://orcid.org/0000-0002-3948-6488)
- Waqqas Afif (ORCID: https://orcid.org/0000-0001-6869-0982)
- Talat Bessissow (ORCID: https://orcid.org/0000-0003-2610-1910)
- Alain Bitton
- Ingrid Candel
- Joaquin Ongay
Institutions
- University of Mendoza (AR)
- Semmelweis University (HU)
- McGill University Health Centre (CA)
Publication Details
- Journal
- Case Reports in Gastroenterology
- Published
- 2025-09-04
- DOI
- https://doi.org/10.1159/000547522
- Primary Topic
- Autoimmune and Inflammatory Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00